Skip to main content


Ovarian Cancer

Featured

Quiz
True or False: In comparison with a biomarker-based strategy, first-line niraparib-for-all maintenance therapy is a cost-effective approach for commercially insured patients with…
Videos
Sandeep Voleti, BS, discusses a study evaluating monetary trends in Medicare reimbursement for radical hysterectomy and…
Conference Coverage
A study presented at the virtual 2021 Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer compared…
Conference Coverage
In comparison with a biomarker-based strategy, first-line niraparib-for-all maintenance therapy is cost-effective for…
Conference Coverage
Minimally invasive surgery is cost-effective compared with laparotomy for suspicious ovarian masses, even though it is…
Back to Top